

HEALTH PLAN POLICY	
Policy Title: Proton Beam Radiotherapy (PBRT)	Policy Number: MUM41 Revision: A
Department: Medical Management	Sub-Department: Utilization Management
Applies to Product Lines: <input type="checkbox"/> Medicaid <input type="checkbox"/> Children's Health Insurance Plan <input checked="" type="checkbox"/> Health Insurance Exchange <input checked="" type="checkbox"/> Medicare <input checked="" type="checkbox"/> USFHP <input checked="" type="checkbox"/> Commercial Insured <input type="checkbox"/> Non Insured Business	
Origination/Effective Date: 02/22/2018	
Reviewed Date(s):	Revision Date(s): 04/24/2019

SCOPE:

Proton beam radiotherapy is a form of external beam radiotherapy. Proton beam centers are limited in number largely to major academic medical centers. They have been studied for decades in a variety of both benign and malignant tumors throughout the body. This policy reviews what is medically necessary based on the evidence based, peer reviewed literature.

DEFINITIONS AND ACRONYMS:

- **Age related Macular Degeneration (AMD)**
- **Agency Health Research and Quality (AHRQ)**
- **American Society of Therapeutic Radiology and Oncology (ASTRO)**
- **Arteriovenous Malformation (AVM)**
- **Central Nervous System (CNS)**

POLICY:

- A. Medical necessity has been identified as present in the following six instances, most of which are CNS based:
1. Uveal melanomas of the eye without metastases
 2. Post-operative therapy of CNS chordomas
 3. Pituitary adenomas
 4. Intracranial AVM's that are non-operable
 5. CNS tumors near critical structures (optic nerve, brain stem or spinal cord)
 6. Pediatric solid tissue tumors where cure is probable
- B. Lack of Medical Necessity is present in the following instances:
1. Age related macular degeneration (AMD)
 2. Prostate cancer
 3. Lung cancer
 4. Head and neck cancer

HEALTH PLAN POLICY

Policy Title: Proton Beam Radiotherapy (PNRT)

Policy Number: MUM41

Revision: A


- 5. Hepatocellular cancer (HCC)
- 6. Esophageal cancer

REFERENCES:

- AHRQ 2014 Prostate Cancer
- ASTRO


RELATED DOCUMENTS:

None



Nancy Hörstmann
Chief Executive Officer Health Plans

5/7/19
Date



David Engleking, M.D.
Medical Director

5/1/19
Date

REVISION HISTORY:

Revision	Date	Description of Change	Committee
New	02/22/2018	Initial release.	Executive Leadership
A	04/24/2019	Annual review. Product lines updated.	Executive Leadership